Study title: A Four-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multi-Center Study of VENTOLIN™ (albuterol) HFA MDI delivered with facemask and two different holding chambers in Subjects aged 24 to <48 months with asthma symptoms (i.e. wheeze, cough, dyspnea or chest tightness) or consistent with asthma or obstructive airway disease or bronchospasm.
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Respiratory Tract Diseases | |||||
| Brands: Please see report, Please see report, Please see report | |||||
| MAH holders: Please see report, Please see report, Please see report | |||||
| Assessment: | |||||
| Active substance: SALBUTAMOL | |||||
| ATC code: | |||||
| Document link: Salbutamol Sulphate-SB020001-ICHE3.pdf | |||||
| Document date: 2011-10-20 | |||||
| Study number: SB020001 | |||||
| EudraCT number: | |||||
| Scope of study: | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | - | |